Angiogenesis markers after hepatic artery embolization of liver metastases in patients with neuroendocrine tumors Abstract #77

Introduction: In the event of diffuse hepatic metastases, hepatic artery embolization (HAE) can be a successful treatment option in patients with well-differentiated neuroendocrine tumors (WNET). Although there are suggestions of activation of the angiogenesis by HAE, no information is available about the development of growth factors caused by vascular obstruction with embolization.
Aim(s): To investigate angiogenesis activity following embolization by measuring of vascular endothelial growth factor (VEGF), endothelin-1 (ET) and C-terminal pro-Endothelin-1 (proET). To examine necrosis activity MonoTotal (MT), a cytokeratin marker, was measured.
Materials and methods: Between 2003 and 2008, 12 patients (M/F: 6/6, age (mean ± SD): 59 ± 9 years) were treated with transcatheter embolization. Blood was obtained before embolization and the days following this treatment during hospitalization. VEGF and ET were measured with ELISA kits (R&D Systems, Minneapolis, USA) and proET levels was measured with an immunoassay (BRAHMS AG; Hennigsdorf, Germany). MT was measured with an IRMA-assay (IDL Biotech AB, Bromma, Sweden).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MSc Catharina M Korse

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2685 Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models
Introduction: Angiogenesis has a pivotal role in the growth and metastasis of pancreatic neuroendocrine tumors (PNETs). Apatinib inhibits angiogenesis as a highly selective KDR inhibitor and has been used to treat advanced gastric cancer and malignancies in clinical settings. However, the efficacy of apatinib in PNETs remains unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Shan Wu
Authors: Wu S, Zhou J, Guo J, Hua Z, ...
#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)
Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Ph.D. Arthur Braat
Authors: Braat A, Rutger B, Van Rooij R, Braat M, ...
#2835 Primary Hepatic Neuroendocrine Carcinoma: Case Report and Literature Review
Introduction: Primary hepatic neuroendocrine carcinoma (PHNEC) is an extremely rare neuroendocrine carcinoma (NEC) that originate from the liver. The diagnosis of PHNEC remains challenging because of its rarity, and its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Saidi M A, Ghomari S, ...
#3032 Lung Side and Site: The Importance of Location and the Prognostic Implication in Lung Neuroendocrine Tumors
Introduction: Lung neuroendocrine tumors (NET) are classified as typical (TC) and atypical carcinoids (AT), according to their mitotic count and the presence of necrosis. However, a role for tumor side (right vs left) and location (central vs peripheric) has not been established so far.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: MD Anna La Salvia
#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Valentina Andreasi